COMMITMENTS AND CONTINGENCIES - Narrative (Details)		9 Months Ended
	Jul. 29, 2019 USD ($)	Sep. 30, 2021 USD ($) liability	Dec. 31, 2020 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Arkis
Loss Contingencies [Line Items]
Purchase price of business combination	$ 30,600,000
Contingent consideration, estimated fair value	25,500,000
Contingent consideration	13,100,000	$ 14,600,000		$ 14,200,000
Arkis | Other Long-term Liabilities | Fair Value, Inputs, Level 3 | Contingent Consideration Liability
Loss Contingencies [Line Items]
Additions from acquisition of ACell		14,617,000	$ 11,746,000	14,165,000	$ 14,210,000
Arkis | Development Milestones
Loss Contingencies [Line Items]
Contingent consideration, estimated fair value	10,000,000.0
Arkis | Commercial Sales Milestones
Loss Contingencies [Line Items]
Contingent consideration, estimated fair value	$ 15,500,000
Derma Sciences
Loss Contingencies [Line Items]
Contingent consideration, estimated fair value		$ 200,000		200,000
Number of contingent liabilities remaining | liability		1
Contingent consideration, maximum undiscounted payment amount		$ 3,000,000
Derma Sciences | Other Long-term Liabilities | Fair Value, Inputs, Level 3 | Contingent Consideration Liability
Loss Contingencies [Line Items]
Additions from acquisition of ACell		230,000	$ 230,000	$ 230,000	$ 230,000
Derma Sciences | BioD Earnout Payments and Medihoney Earnout Payments
Loss Contingencies [Line Items]
Payment for contingent consideration		$ 33,300,000